[Medical Treatments in Oncology 2023].
innovation
oncology
survival
therapy
Journal
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
ISSN: 1724-5990
Titre abrégé: G Ital Nefrol
Pays: Italy
ID NLM: 9426434
Informations de publication
Date de publication:
03 Oct 2023
03 Oct 2023
Historique:
medline:
28
11
2023
pubmed:
26
11
2023
entrez:
26
11
2023
Statut:
epublish
Résumé
Medical Oncology since the beginning of the new millennium has recognized a great positive evolution in the care of cancer. In fact, for more than 60 years the two classical pillars of the antineoplastic therapy were hormone therapies mainly applied in breast, prostate and thyroid cancer, and chemotherapy seldom curative and heavily toxic. Nowadays some new treatments are available thanks to the advances in genomics, proteomics and molecular biology of tumor cells either to the advances in immunology studies. Specific pathways in cancer cells have been recognized and hit by targeted drugs. Monoclonal antibodies, tyrosine kinase inhibitors, checkpoint inhibitors, cellular therapies and vaccines are the new tools for oncologists. The last discovery is the antibody-drug conjugates (ADCs), which combine monoclonal antibodies with cytotoxic drugs. Unfortunately, these impressive advances have caused the appearance of new scientific, social, and financial problems. All these topics are discussed in the article.
Substances chimiques
Antineoplastic Agents
0
Antibodies, Monoclonal
0
Types de publication
English Abstract
Journal Article
Review
Langues
ita
Sous-ensembles de citation
IM
Informations de copyright
Copyright by Società Italiana di Nefrologia SIN, Rome, Italy.